Entry-into-humans study with a new direct renin inhibitor

European Journal of Clinical Pharmacology

Volumn 68, Issue 9, 2012, Pages 1257-1266

  Nicolas, Laurent B ^a   Gutierrez, Marcelo M ^a   Binkert, Christoph ^a   Dingemanse, Jasper ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

Healthy subjects; Pharmacodynamics; Pharmacokinetics; Renin inhibitor

Indexed keywords

3,7,9 DIAZA BICYCLO[3.3.1]NON 6 ENE 6 CARBOXYLIC ACID CYCLOPROLYL (2,3 DIMETHYLBENZYL)AMIDE; ACT 077825; ENALAPRIL; ENALAPRILAT; PLACEBO; RENIN; RENIN INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; FATIGUE; FLATULENCE; HARD FECES; HEADACHE; HUMAN; HUMAN EXPERIMENT; HYPERHIDROSIS; LIMIT OF QUANTITATION; MALE; NAUSEA; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PLASMA RENIN ACTIVITY; POSITIONAL DIZZINESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; SYNCOPE; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; AREA UNDER CURVE; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENALAPRIL; HALF-LIFE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; RENIN; SWITZERLAND; TOLUENE; YOUNG ADULT;

EID: 84866622223     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1253-2     Document Type: Article

References (18)

1. Ma TK, Kam KK, Yan BP, Lam YY (2010) Renin-angiotensinaldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol 160(6):1273-1292
2. Perret-Guillaume C, Joly L, Jankowski P, Benetos A (2009) Benefits of the RAS blockade: clinical evidence before the ONTARGET study. J Hypertens Suppl 27(2):S3-S7
3. Bing J (1973) Rapid marked increase in plasma renin in rats treated with inhibitors of the renin system. Effects of 1-sar-8-ala-angiotensin II and of a synthetic converting enzyme inhibitor (nonapeptide, SQ 20.881) on normal and adrenalectomized rats. Acta Pathol Microbiol Scand A 81(3):376-378
4. Doggrell SA, Wanstall JC (2004) Vascular chymase: pathophysiological role and therapeutic potential of inhibition. Cardiovasc Res 61(1):653-662
5. Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A (1998) Plasma bradykinin in angio-oedema. Lancet 351:1693-1697
6. Siragy HM, Xue C, Abadir P, Carey RM (2005) Angiotensin subtype-2 receptors inhibit renin biosynthesis and angiotensin II formation. Hypertension 45(1):133-137
7. Zhang X, Lassila M, Cooper ME, Cao Z (2004) Retinal expression of vascular endothelial growth factor is mediated by angiotensin type 1 and type 2 receptors. Hypertension 432:276-281
8. Fisher ND, Hollenberg N (1995) Renal vascular responses to renin inhibition with zankiren in men. Clin Pharmacol Ther 57(3):342-348
9. Fisher ND, Hollenberg N (2001) Is there a future for renin inhibitors? Expert Opin Investig Drugs 10(3):417-426
10. Rongen GA, Lenders JW, Smits P, Thien T (1995) Clinical pharmacokinetics and efficacy of renin inhibitors. Clin Pharmacokinet 29(1):6-14
11. Azizi M, Webb R, Nussberger J, Hollenberg NK (2006) Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens 24(2):243-256
12. US prescribing information (2007) Tekturna, aliskiren tablets. Novartis Pharmaceuticals Corporation, East Hanover, NJ
13. Bezencon O, Bur D, Weller T, Richard-Bildstein S, Remen L, Sifferlen T, Corminboeuf O, Grisostomi C, Boss C, Prade L, Delahaye S, Treiber A, Strickner P, Binkert C, Hess P, Steiner B, Fischli W (2009) Design and preparation of potent, nonpeptidic, bioavailable renin inhibitors. J Med Chem 52(12):3689-3702
14. Gough K (1995) Assessment of dose proportionality: reports from the statisticians in the pharmaceutical industry/pharmacokinetics UK joint working group. Drug Inform J 29:1039-1048
15. Daugherty KK (2008) Aliskiren. Am J Health Syst Pharm 65 (14):1323-1332
16. Frampton JE, Curran MP (2007) Aliskiren: a review of its use in the management of hypertension. Drugs 67(12):1767-1792
17. Staessen JA, Li Y, Richart T (2006) Oral renin inhibitors. Lancet 368(9545):1449-1456
18. Nussberger J, Wuerzner G, Jensen C, Brunner HR (2002) Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril. Hypertension 39 (1):E1-E8